Adagio Medical Holdings, Inc.
ADGMHealthcareNASDAQMedical Devices · Last scanned Sep 4, 2026
Scan Results
Daily timeframe1 of 4 indicators bullish as of Sep 3
Headquartered within the healthcare sector, Adagio Medical Holdings, Inc. focuses on Medical Devices services and products. Adagio Medical Holdings, Inc., a medical technology company, focuses on the development and commercialization of ablation technologies for the treatment of cardiac arrhythmias. At a $12.0M market cap, Adagio Medical Holdings, Inc. ranks as a micro-cap company within healthcare. It offers treatment for cardiac arrhythmias, including atrial fibrillation, and ventricular tachycardia.
Market Cap
$12.0M
Beta
-0.15
P/E (TTM)
—
P/E (Fwd)
-0.47
EPS (TTM)
$-1.37
EPS (Fwd)
$-1.16
ROE
-657.8%
ROA
-35.5%
Cash
$7.7M
Total Debt
$26.0M
Free CF
-$7.9M
52W Change
-66.5%
Annual Financials
Cash vs Debt
Where ADGM stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, ADGM finished 39.08% below its 150-day moving average ($0.87) and 40.45% below its 200-day moving average ($0.89). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ADGM overbought or oversold?
At the September 3, 2026 close, ADGM's RSI(14) was 20.1, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $7.7M in cash, though total debt stands at $26.0M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company is burning cash, with free cash flow at -$7.9M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -657.8% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $270K (2021) to $0 (2025), a 100% decline worth watching.
ADGM's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Adagio Medical Holdings, Inc. and its sector.